refractory or relapsed multiple myeloma
Showing 1 - 4 of 4
Refractory or Relapsed Multiple Myeloma Trial (LCAR-B38M CAR-T cell injection)
Unknown status
- Refractory or Relapsed Multiple Myeloma
- LCAR-B38M CAR-T cell injection
- (no location specified)
Aug 31, 2021
Refractory or Relapsed Multiple Myeloma Trial in Shanghai (CAR-BCMA T cells, Fludarabine, Cyclophosphamide)
Active, not recruiting
- Refractory or Relapsed Multiple Myeloma
- CAR-BCMA T cells
- +2 more
-
Shanghai, Shanghai, ChinaXin Hua Hospital of Shanghai Jiao Tong University of Medicine
Oct 8, 2020
Refractory or Relapsed Multiple Myeloma Trial in Hangzhou (CAR-BCMA T cells, Fludarabine, Cyclophosphamide)
Active, not recruiting
- Refractory or Relapsed Multiple Myeloma
- CAR-BCMA T cells
- +2 more
-
Hangzhou, Zhejiang, ChinaFirst Affiliated Hospital of Zhejiang University
Oct 6, 2020
Refractory or Relapsed Multiple Myeloma Trial in Xi'an (LCAR-B4822M CAR-T Cell Immunotherapy)
Unknown status
- Refractory or Relapsed Multiple Myeloma
- LCAR-B4822M CAR-T Cell Immunotherapy
-
Xi'an, Shaanxi, ChinaSecond Affiliated Hospital of Xi'an Jiaotong University
Dec 13, 2018